7402-70-2

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-tert-butylphenyl)acetamide is utilized as a pharmaceutical intermediate for the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Medicinal Applications:
N-(2-tert-butylphenyl)acetamide is employed as an anti-inflammatory and analgesic agent, making it a valuable asset in the creation of novel drug candidates for treating different medical conditions.
Used in Industrial Applications:
N-(2-tert-butylphenyl)acetamide is used as a corrosion inhibitor, playing a crucial role in protecting materials from degradation in various industrial processes.

Upstream product

• 1886-57-3 1-tert-butyl-2-nitrobenzene 
• 108-24-7 acetic anhydride 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 75-36-5 acetyl chloride 
• 100-46-9 benzylamine 
• 318256-54-1 (RS)-N-(2-tert-butylphenyl)-N-pivaloylacetamide 
• 71-43-2 benzene 
• 64-19-7 acetic acid 
• 253185-03-4 tert-butylbenzene 

Downstream Products

• 951-14-4 acetic acid-(2-tert-butyl-N-nitroso-anilide) 
• 850012-44-1 4-bromo-(2-tert-butyl)aniline 
• 41085-44-3 2-tert-butyl-6-nitro-aniline 
• 59255-98-0 2-(tert-butyl)-4-nitroaniline 
• 109774-66-5 Acetyl-(2-tert-butyl-phenyl)-carbamic acid tert-butyl ester 
• 243662-21-7 N-(2-tert-butyl-phenyl)-N-propionyl-acetamide 
• 318233-91-9 (RS)-N-(2-tert-butylphenyl)-N-isovalerylacetamide 
• 243662-21-7 (RS)-N-(2-tert-butylphenyl)-N-propionylacetamide 
• 318256-56-3 (RS)-N-(2-tert-butylphenyl)-N-isobutyrylacetamide 
• 329350-02-9 N-(2-tert-butyl-6-oxo-cyclohexa-2,4-dienylidene)-acetamide 
• 1207442-37-2 C₃₅H₄₅N₃ 
• 342045-15-2 N-(2-tert-butyl-5-nitro-phenyl)-acetamide 
• 1190867-87-8 N-(2-tert-butyl-6-chloro-phenyl)-acetamide 
• 91802-56-1 N-(2-tert-butyl-4-chloro-phenyl)-acetamide 

Relevant academic research and scientific papers

Copper-Catalyzed Amination of C(sp3)-H bonds: From Anilides to Indolines

Copper-catalyzed oxidative intramolecular cyclization of o-alkylated anilines via cleavage of C(sp3)-H and N-H bonds for the production of indolines is described. This approach provides a straightforward strategy for the synthesis of nitrogen-c

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION

Specific polycyclic compounds, a material for an organic electroluminescence device comprising said specific polycyclic compound, an organic electroluminescence device comprising said specific polycyclic compound, an electronic equipment comprising said organic electroluminescence device, a process for preparing said polycyclic compounds, and the use of said polycyclic compounds in an organic electroluminescence. (Formula I) (I)

Air-stable Bis(pentamethylcyclopentadienyl) Zirconium Perfluorooctanesulfonate as an Efficient and Recyclable Catalyst for the Synthesis of N-substituted Amides

Bis(pentamethylcyclopentadienyl) zirconium perfluorooctanesulfonate is an air-stable and water-tolerant Lewis acid. This complex exhibited good thermal stability and high solubility in polar organic solvents. The compound showed relatively strong acidity, with an acid strength of 0.8Ho≤3.3, and high catalytic efficiency for the synthesis of N-substituted amides via the reaction of carboxylic acids with amines, the Ritter reaction of nitriles with alcohols, and the amination of alcohols with amides. Moreover, the complex had good reusability. This catalytic system affords a simple and efficient way to synthesize N-substituted amides.

Sulfated choline ionic liquid-catalyzed acetamide synthesis by grindstone method

Sulfated choline ionic liquid (SCIL) has been found to be an efficient solid acid IL catalyst for the protection of amine groups with acetic anhydride under solvent-free grindstone conditions. The attractive features of this new catalytic methodology include its sustainability, facile work-up procedure, economic viability, and biodegradability. The SCIL catalyst was characterized using infrared spectroscopy, wide-angle X-ray scattering analysis, and scanning electron microscopy with energy dispersive X-ray spectroscopy. The catalyst could be reused six times without significant loss in activity. Furthermore, no chromatographic separations were needed to obtain the desired products.

Cu-Catalyzed Intramolecular Amidation of Unactivated C(sp3)-H Bonds to Synthesize N-Substituted Indolines

A copper-catalyzed intramolecular amidation of unactivated C(sp3)-H bonds to construct indoline derivatives has been developed. Such an amidation proceeded well at primary C-H bonds preferred to secondary C-H bonds. The transformation owned a b

Catalytic C(sp3)?H Arylation of Free Primary Amines with an exo Directing Group Generated In Situ

Herein, we report the palladium-catalyzed direct arylation of unactivated aliphatic C?H bonds in free primary amines. This method takes advantage of an exo-imine-type directing group (DG) that can be generated and removed in situ. A range of unprotected aliphatic amines are suitable substrates, undergoing site-selective arylation at the γ-position. Methyl as well as cyclic and acyclic methylene groups can be activated. Furthermore, when aniline-derived substrates were used, preliminary success with δ-C?H arylation was achieved. The feasibility of using the DG component in a catalytic fashion was also demonstrated.

DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors

Novel ligand compounds that activate RAR receptors have the following structural formula (I): and are suited for formulation into pharmaceutical compositions useful in human or veterinary medicine, or, alternatively, into cosmetic compositions.